CI

At a glance

ClinicalIndex Comparison Record
Phase 3Unknown· 120 target
Drug / intervention
PBSC +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02240992
NCT02240992Phase 3Unknown

Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant

Nanfang Hospital, Southern Medical University·interventional·Posted Sep 16, 2014·Updated Sep 16, 2014

In Brief

A Phase 3 clinical trial evaluating PBSC and MSCs for Stem Cell Transplantation, Hematopoietic and 3 related conditions. Targeting 120 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the efficacy of mesenchymal stem cells (MSCs) with or without granulocyte colony-stimulating factor (G-CSF) mobilized peripheral stem cells (PBSC) in treating patients experiencing poor graft function or delayed platelet engraftment after allogeneic hematopoietic stem cell transplantation.

Study Details

Timeline

Phase 3UnknownOverdue
201520162017201820192020202120222023202420252026
First PostedSep 16, 2014
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2018
Study CompletionDec 1, 2018
TodayJul 1, 2026
Enrollment to primary: 4 yearsPosted 11.8 years ago

Interventions

PBSCbiological

MSCsbiological